Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 daratumumab-based therapies in newly diagnosed AL amyloidosis
NL-OMON51367Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in light-chain amyloidosis (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Cardiac safety characterization in Cohort 1 and Pharmacokinetics of subcutaneous daratumumab in Cohort 2. Started Mar 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NL-OMON51367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51367.